We came across a bullish thesis on Merus N.V. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on MRUS. Merus N.V.'s share was trading at $95.99 as of December 2nd.
[caption id="attachment_1617126" align="aligncenter" width="768"]Genmab’s acquisition of Merus for $97 per share has been well received by the market, with Genmab’s stock reacting positively despite the deal’s significant size. The transaction reflects continued consolidation in the biotech sector,...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.